Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …

Summary Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Protein kinases play a major role in cellular activation processes, including signal
transduction by diverse immunoreceptors. Given their roles in cell growth and death and in …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus
disease 2019 (COVID-19), a rapidly evolving pandemic worldwide with at least 68 million …

Although historically, the traditional bidimensional in vitro cell system has been widely used
in research, providing much fundamental information regarding cellular functions and …